Pouyan Famini, M.D.

2.2 times the Medicare Part D claims of the average endocrinology, diabetes & metabolism physician in 2024

5,677 Medicare Part D claims for 605 beneficiaries, against an average of 2,630 among the 8,223 providers of this specialty who prescribed in Part D. Brand-name drugs were 44% of claims.

Most prescribed

1. Levothyroxine Sodium562 claims
2. Ozempic373 claims
3. Metformin Hcl Er328 claims
4. Metformin Hcl287 claims
5. Trulicity255 claims
6. Mounjaro251 claims

Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.

The practice group's MIPS final score for 2023 (Medicare payment program): 86.1 of 100

The Merit-based Incentive Payment System score is reported for the practice group, not for one clinician alone. Four categories are weighted into the final score; the average among 454,083 clinicians with a measured score was 83.5.

Source: CMS Quality Payment Program, MIPS performance year 2023, group reporting; category weights for 2023 (qpp.cms.gov).

Industry payments in 2024: $18.67

1 payment: food and beverage; the largest payer was Abbott Laboratories. The 5,661 providers of this specialty with any payment received $5,742.15 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.

Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.

Bills Medicare through one group practice

1. The Regents OF The University OF CaliforniaLos Angeles, CA

Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).